By Laura Barron-Lopez | POLITICO
The White House has a new headache as it struggles to get its multitrillion-dollar party-line spending bill passed: Sen. Kyrsten Sinema’s objections to drug pricing reforms that are already struggling to make it through the House.
The Arizona Democrat is opposed to the current prescription drug pricing proposals in both the House and Senate bills, two sources familiar with her thinking said. They added that, at this point, she also doesn’t support a pared-back alternative being pitched by House Democratic centrists that would limit the drugs subject to Medicare negotiation.
Sinema met with President Joe Biden on Sept. 15 to discuss the social spending package, in which party leaders hope to include the Medicare prescription drug pricing proposal. Sinema has made her resistance to the current House prescription drug negotiation proposal clear to the White House, according to one of the sources, but it’s unclear if she’s completely immovable.
Both she and Sen. Joe Manchin (D-W.Va.), who met with the president the same day, delivered what one source described as a sobering message for the White House about the fate of the reconciliation bill and its $3.5 trillion price tag, which they both say is too high. The social spending plan is designed to pass without GOP votes through budget reconciliation, meaning that Biden will need to win all 50 Senate Democratic votes to secure its passage.